Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Core Insights - Immuneering Corporation is progressing well in its IMM-1-104 Phase 2a trial, with initial data from multiple arms expected in the second half of 2024 [1][2] - The FDA has granted Fast Track designation for IMM-1-104 as a first-line treatment for pancreatic ductal adenocarcinoma (PDAC) [3] - Preclinical data indicates that combining IMM-1-104 with established chemotherapy regimens results in deeper and more durable tumor growth inhibition compared to either treatment alone [4] Company Updates - The company reported a cash position of $59.7 million as of June 30, 2024, down from $85.7 million at the end of 2023 [5] - Research and Development (R&D) expenses for Q2 2024 were $10.7 million, an increase from $9.5 million in Q2 2023, primarily due to higher clinical costs [6] - General and Administrative (G&A) expenses for Q2 2024 were $4.3 million, up from $4.0 million in the same period last year, attributed to increased stock-based compensation [7] Financial Performance - The net loss for Q2 2024 was $14.1 million, or $0.47 per share, compared to a net loss of $12.2 million, or $0.43 per share, in Q2 2023 [8] - The company expects its cash runway to be sufficient to fund operations into the second half of 2025 based on current cash and operating plans [9]